Aus­tralian cell ther­a­py com­pa­ny Mesoblast joins forces with Ger­many's Grü­nen­thal to tack­le low back pain

While the FDA re­views a rolling ap­pli­ca­tion for its ex­per­i­men­tal stem cell ther­a­py for acute graft ver­sus host dis­ease (GVHD), Aus­tralia’s Mesoblast has tied up …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER